None
DE
HLA Protein Technologies’ secures an internal use license from the National Cancer Institute (NCI)
['Terry Windall', 'Terry Windall Is The Managing Content Editor For Massachusetts Newswire', 'Has Been A Team Member Of The Neotrope', 'News Network Since March She Is Currently Attending Art College', 'Blames Red Bull For Not Giving Her Wiings To Fly Away. She Her Is Transitioning A He Him In She Was A Huge Jj Abrams Fan Until He Ruined Star Wars', 'But Otherwise A Huge Pop Culture Fan.']
Massachusetts Newswire
NATIONAL NEWS (OKLAHOMA CITY, Okla.) — — HLA Protein Technologies, Inc. (formerly Pure Protein, LLC), a global leader in soluble, natively folded HLA proteins and custom peptide binding services, announced a major step forward for TCR research.
RAISING THE BAR FOR TCR RESEARCHBuilding on the discoveries this license unlocks, HLA Protein Technologies is bridging its market-leading HLA Peptide Binding Services to deliver tetramer-level signal in days, not months.
Dr. Rico Buchli, Chief Scientific Officer at HLA Protein Technologies said that this NCI license reflects HLA Protein Technologies’ commitment to delivering best-in-class HLA and tetramer products and services for TCR research.
ABOUT HLA PROTEIN TECHNOLOGIES, INC.Based in Oklahoma City, HLA Protein Technologies offers the industry’s broadest portfolio of soluble, natively folded recombinant HLA proteins and HLA tetramer reagents supporting T-cell research, B-cell research, TCR discovery and anti-HLA antibody detection and characterization.
With more than 25 years of HLA expertise, HLA Protein Technologies delivers solutions that advance immunotherapy, oncology and transplant science in over 20 countries.